id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-4282-0012,FDA,FDA-2017-E-4282,"Determination of Regulatory Review Period for Purposes of Patent
Extension; TRULANCE",Notice,Determinations,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,2019-02-05T04:59:59Z,2019-01-30T02:05:27Z,2018-26289,0,0,09000064839390a7
FDA-2017-E-4282-0011,FDA,FDA-2017-E-4282,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-11-20T05:00:00Z,2018,11,2018-11-20T05:00:00Z,,2018-11-20T13:06:21Z,,0,0,09000064838eb872
FDA-2017-E-4282-0010,FDA,FDA-2017-E-4282,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T13:04:03Z,,0,0,090000648378acad